» Articles » PMID: 28580898

Increased Cardiovascular Mortality in People with Schizophrenia: a 24-year National Register Study

Overview
Date 2017 Jun 6
PMID 28580898
Citations 66
Authors
Affiliations
Soon will be listed here.
Abstract

Methods: This national register study of 10 631 817 people in Sweden included 46 911 people who were admitted to the hospital for schizophrenia between 1 January 1987 and 31 December 2010. Information from national registers was used to identify people who had schizophrenia and obtain data about mortality, causes of death, medical diagnoses and hospitalisations.

Results: CVDs were the leading cause of death in people who had schizophrenia (5245 deaths), and CVDs caused more excess deaths than suicide. The mean age of CVD death was 10 years lower for people who had schizophrenia (70.5 years) than the general population (80.7 years). The mortality rate ratio (MRR) for CVDs in all people who had schizophrenia was 2.80 (95% confidence interval (CI) 2.73-2.88). In people aged 15-59 years who had schizophrenia, the MRR for CVDs was 6.16 (95% CI 5.79-6.54). In all people who had schizophrenia, the MRR for coronary heart disease was 2.83 (95% CI 2.73-2.94); acute myocardial infarction, 2.62 (95% CI 2.49-2.75); cerebrovascular disease, 2.4 (95% CI 2.25-2.55); heart failure, 3.25 (95% CI 2.94-3.6); and cardiac arrhythmias, 2.06 (95% CI 1.75-2.43). Hospital admissions for coronary heart disease were less frequent in people who had schizophrenia than in the general population (admission rate ratio, 0.88 (95% CI 0.83-0.94). In all age groups, survival after hospital admission for CVD was lower in people who had schizophrenia than in the general population.

Conclusions: People who had schizophrenia died 10 years earlier from CVDs than did people in the general population. For all five CVD diagnoses, mortality risk was higher for those with schizophrenia than those in the general population. Survival after hospitalisation for CVDs in people who had schizophrenia was comparable with that of people in the general population who were several decades older.

Citing Articles

Cardiovascular comorbidities in Chinese inpatients with schizophrenia spectrum disorders.

Dong Z, Wu G, Liu H, Chen S, Bi B, Zhang F Schizophrenia (Heidelb). 2025; 11(1):22.

PMID: 39971916 PMC: 11840127. DOI: 10.1038/s41537-025-00576-3.


The role of anti-inflammatory diets and supplementation in metabolic syndrome and symptom remission in adults with schizophrenia: a systematic review.

Suschana E, Anderson T, Hong C, Narikatte A, Silverberg J, Sharma M Front Psychiatry. 2025; 15():1506353.

PMID: 39839138 PMC: 11747649. DOI: 10.3389/fpsyt.2024.1506353.


Increased mortality risk in people with schizophrenia in Lithuania 2001-2020.

Drevinskaite M, Kaceniene A, Germanavicius A, Smailyte G Schizophrenia (Heidelb). 2025; 11(1):7.

PMID: 39820533 PMC: 11739394. DOI: 10.1038/s41537-024-00549-y.


Association between psychiatric disorders and the risk of stroke: a meta-analysis of cohort studies.

Hu Z, Sun W, Cui E, Chen B, Zhang M Front Neurol. 2025; 15:1444862.

PMID: 39744110 PMC: 11688293. DOI: 10.3389/fneur.2024.1444862.


Beyond the Heart: The Predictive Role of Coronary Artery Calcium Scoring in Non-Cardiovascular Disease Risk Stratification.

Cortiana V, Vaghela H, Bakhle R, Santhosh T, Kaiwan O, Tausif A Diagnostics (Basel). 2024; 14(21).

PMID: 39518317 PMC: 11545064. DOI: 10.3390/diagnostics14212349.


References
1.
Barnes T, Paton C, Cavanagh M, Hancock E, Taylor D . A UK audit of screening for the metabolic side effects of antipsychotics in community patients. Schizophr Bull. 2007; 33(6):1397-403. PMC: 2779874. DOI: 10.1093/schbul/sbm038. View

2.
Chugh S, Jui J, Gunson K, Stecker E, John B, Thompson B . Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate-based review in a large U.S. community. J Am Coll Cardiol. 2004; 44(6):1268-75. DOI: 10.1016/j.jacc.2004.06.029. View

3.
Osby U, Westman J, Hallgren J, Gissler M . Mortality trends in cardiovascular causes in schizophrenia, bipolar and unipolar mood disorder in Sweden 1987-2010. Eur J Public Health. 2016; 26(5):867-871. PMC: 5054269. DOI: 10.1093/eurpub/ckv245. View

4.
Mackin P, Bishop D, Watkinson H, Ferrier I . A prospective study of glycaemic status in anti-psychotic-treated patients. J Psychopharmacol. 2008; 22(5):563-6. DOI: 10.1177/0269881107081532. View

5.
Olsson E, Westman J, Hukic D, Eriksson S, Edman G, Boden R . Diabetes and glucose disturbances in patients with psychosis in Sweden. BMJ Open Diabetes Res Care. 2015; 3(1):e000120. PMC: 4600183. DOI: 10.1136/bmjdrc-2015-000120. View